BAILEY MICHAEL P 4
4 · AVEO PHARMACEUTICALS, INC. · Filed Dec 22, 2022
Insider Transaction Report
Form 4
BAILEY MICHAEL P
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2022-12-20$5.60/sh+85,722$480,043→ 175,642 total - Exercise/Conversion
Common Stock
2022-12-20$3.67/sh+164,525$603,807→ 340,167 total - Exercise/Conversion
Stock Option (right to buy)
2022-12-20−85,722→ 35,302 totalExercise: $5.60Exp: 2030-02-05→ Common Stock (85,722 underlying) - Exercise/Conversion
Stock Option (right to buy)
2022-12-20−164,525→ 625,192 totalExercise: $3.67Exp: 2032-02-15→ Common Stock (164,525 underlying) - Exercise/Conversion
Common Stock
2022-12-20$6.20/sh+26,499$164,294→ 82,920 total - Exercise/Conversion
Stock Option (right to buy)
2022-12-20−26,499→ 93,500 totalExercise: $6.20Exp: 2029-02-06→ Common Stock (26,499 underlying)
Footnotes (4)
- [F1]Includes 7,110 shares purchased by the Reporting Person under the Company's 2010 Employee Stock Purchase Plan, as amended.
- [F2]The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company.
- [F3]The shares underlying this option vest in equal monthly installments from February 5, 2020 through February 5, 2024, subject to the Reporting Person's continued service to the Company.
- [F4]The shares underlying this option vest in equal monthly installments from February 15, 2022 through February 15, 2026, subject to the Reporting Person's continued service to the Company.